Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase II Trial Evaluating Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)

NCT06088381 is registered in ClinicalTrials.gov with University of Maryland, Baltimore as lead sponsor.

NCT NCT06088381
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06088381 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase II Trial Evaluating Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)
Lead sponsor
University of Maryland, Baltimore
Phase
Phase 2
Overall status
Recruiting
Start date
March 7, 2024
Completion date
December 18, 2030
Enrollment
61 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck cancer, head and neck squamous cell carcinoma, hpv positive oropharyngeal squamous cell carcinoma, oropharynx cancer, oropharynx squamous cell carcinoma